IMPLANT ALTERNATIVES LTD

• ⚠

  Material uncertainty over going concern

  The financial statements have been prepared on a going concern basis. As at 31 December 2024, the Company had net liabilities of £4,771k (2023: net liabilities of £4,390k) and net current liabilities of £4,771k (2023: net current liabilities of £4,390k). At the balance sheet date, the company owed monies to fellow group companies of £4,776k. In response to the net current liabilities position, net liabilities position and intercompany borrowings position, when performing their going concern assessment, which covers the period through to 31 March 2027, the directors have obtained a parental support letter from Femur Buyer Inc ("US Group") to support their going concern conclusions. These circumstances indicate the existence of material uncertainties related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The financial statements have been prepared on a going concern basis. As at 31 December 2024, the Company had net liabilities of £4,771k (2023: net liabilities of £4,390k) and net current liabilities of £4,771k (2023: net current liabilities of £4,390k). At the balance sheet date, the company owed monies to fellow group companies of £4,776k. In response to the net current liabilities position, net liabilities position and intercompany borrowings position, when performing their going concern assessment, which covers the period through to 31 March 2027, the directors have obtained a parental support letter from Femur Buyer Inc ("US Group") to support their going concern conclusions. These circumstances indicate the existence of material uncertainties related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern”

Significant events

• “In late October 2025, Femur Buyer, Inc. group (the "Group") restructured its outstanding debt, strengthening Femur Buyer Inc Groups' liquidity. As part of this transaction, all of its outstanding second lien debt was exchanged for common equity and a portion of its first lien debt was exchanged for preferred equity.”
• “In addition, the directors of Femur Buyer Inc have signed a merger deal with Tecomet on 14 January 2026, to improve cost synergies in the long term, subject to Regulatory approval and closing conditions. The merger will not be final until no earlier than Q2 2026 and both companies will continue to operate separately until Regulatory approval is complete.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.